Alnylam Pharmaceuticals, Inc. (ALNY)
收市後：
| 前收市價 | 237.88 |
| 開市 | 237.20 |
| 買盤 | 234.67 x 100 |
| 賣出價 | 234.97 x 100 |
| 今日波幅 | 233.42 - 240.31 |
| 52 週波幅 | 141.98 - 263.73 |
| 成交量 | |
| 平均成交量 | 1,028,688 |
| 市值 | 29.705B |
| Beta 值 (5 年，每月) | 0.37 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.64 |
| 業績公佈日 | 2024年8月01日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 261.15 |
ZacksAlnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- InvestorPlace
Alnylam Stock Is a Blockbuster Biopharma In the Making
Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ:ALNY) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has several drugs already on the market, the biopharma is not yet profitable. But if Alnylam can gain expedited approval from the FDA for its RNA interference drug vutrisiran, that could change quickly. Alnylam stock soared 31% on positive Phase 3 trial news and continued rising afterward. Getting vutrisira
- InvestorPlace
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.
Could Alnylam Pharmaceuticals (NASDAQ:ALNY) become a household name in 2024? At the very least, the company should be well known in the medical community. If you like to wager small amounts of money on biotechnology stocks, then you really ought to consider Alnylam Pharmaceuticals stock. As we’ll discuss in a moment, Alnylam Pharmaceuticals didn’t start off 2024 with perfect financials. However, a recent announcement indicates a breakthrough moment for Alnylam Pharmaceuticals and, potentially, f
